Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia

A. Benigni, P. Boccardo, M. Galbusera, J. Monteagudo, L. De Marco, G. Remuzzi, Z. M. Ruggeri

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Patients with chronic renal failure may experience a bleeding tendency and blood loss after surgical procedures or trauma. Altered platelet function has been indicated as the major cause of uremic bleeding, but its pathogenesis remains to be clarified. In two groups of patients with chronic renal disease of various etiology, the receptor function of glycoprotein (GP) Ib and GP IIb-IIIa complex was studied. Glycoprotein Ib was assessed with both 125I- von Willebrand factor (vWF) and 125I-asialo-vWF binding to platelets. Activation-dependent receptor function of the GP IIb-IIIa complex was studied with 125I-fibrinogen and 125I-vWF binding to washed platelets stimulated with adenosine diphosphate plus epinephrine (10 μmol/L each). Flow cytometric analyses on resting and stimulated platelets were performed using an activation-dependent, anti-GP IIb-IIIa monoclonal antibody (PAC1) as well as an activation-independent antibody (LJ-P1). Binding of PAC1 also was assessed in washed and stimulated platelets and in platelet-rich plasma before and after dialysis. We found that the activation-dependent receptor function of the GP IIb-IIIa complex is defective in uremia, as shown by decreased binding of both vWF and fibrinogen to stimulated platelets. Moreover, binding of the activation-dependent anti-GP IIb-IIIa monoclonal antibody, PAC1, was significantly decreased in uremia compared with that of the activation-independent antibody, LJ-P1. Thus, the number of GP IIb-IIIa receptors expressed on the platelet membrane is normal, but their activation is impaired. In contrast to the functional abnormality of GP IIb-IIIa, the vWF-binding activity of GP Ib was normal. Removal of components present in uremic plasma, either 'in vitro' by platelet washing or 'in vivo' by hemodialysis, markedly improved the GP IIb-IIIa defect. We conclude that a reversible abnormality of the activation-dependent binding activity of GP IIb-IIIa, due to dialyzable toxic substances, is likely to be a major component of the altered platelet function in uremia.

Original languageEnglish
Pages (from-to)668-676
Number of pages9
JournalAmerican Journal of Kidney Diseases
Volume22
Issue number5
Publication statusPublished - 1993

Fingerprint

Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Uremia
Blood Platelets
von Willebrand Factor
Platelet Glycoprotein GPIb-IX Complex
Fibrinogen
Monoclonal Antibodies
Surgical Blood Loss
Hemorrhage
Platelet-Rich Plasma
Antibodies
Poisons
Chronic Renal Insufficiency
Adenosine Diphosphate
Epinephrine
Chronic Kidney Failure
Renal Dialysis
Dialysis

ASJC Scopus subject areas

  • Nephrology

Cite this

Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. / Benigni, A.; Boccardo, P.; Galbusera, M.; Monteagudo, J.; De Marco, L.; Remuzzi, G.; Ruggeri, Z. M.

In: American Journal of Kidney Diseases, Vol. 22, No. 5, 1993, p. 668-676.

Research output: Contribution to journalArticle

@article{f9359191ece74c9da327fed5146e6c42,
title = "Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia",
abstract = "Patients with chronic renal failure may experience a bleeding tendency and blood loss after surgical procedures or trauma. Altered platelet function has been indicated as the major cause of uremic bleeding, but its pathogenesis remains to be clarified. In two groups of patients with chronic renal disease of various etiology, the receptor function of glycoprotein (GP) Ib and GP IIb-IIIa complex was studied. Glycoprotein Ib was assessed with both 125I- von Willebrand factor (vWF) and 125I-asialo-vWF binding to platelets. Activation-dependent receptor function of the GP IIb-IIIa complex was studied with 125I-fibrinogen and 125I-vWF binding to washed platelets stimulated with adenosine diphosphate plus epinephrine (10 μmol/L each). Flow cytometric analyses on resting and stimulated platelets were performed using an activation-dependent, anti-GP IIb-IIIa monoclonal antibody (PAC1) as well as an activation-independent antibody (LJ-P1). Binding of PAC1 also was assessed in washed and stimulated platelets and in platelet-rich plasma before and after dialysis. We found that the activation-dependent receptor function of the GP IIb-IIIa complex is defective in uremia, as shown by decreased binding of both vWF and fibrinogen to stimulated platelets. Moreover, binding of the activation-dependent anti-GP IIb-IIIa monoclonal antibody, PAC1, was significantly decreased in uremia compared with that of the activation-independent antibody, LJ-P1. Thus, the number of GP IIb-IIIa receptors expressed on the platelet membrane is normal, but their activation is impaired. In contrast to the functional abnormality of GP IIb-IIIa, the vWF-binding activity of GP Ib was normal. Removal of components present in uremic plasma, either 'in vitro' by platelet washing or 'in vivo' by hemodialysis, markedly improved the GP IIb-IIIa defect. We conclude that a reversible abnormality of the activation-dependent binding activity of GP IIb-IIIa, due to dialyzable toxic substances, is likely to be a major component of the altered platelet function in uremia.",
author = "A. Benigni and P. Boccardo and M. Galbusera and J. Monteagudo and {De Marco}, L. and G. Remuzzi and Ruggeri, {Z. M.}",
year = "1993",
language = "English",
volume = "22",
pages = "668--676",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia

AU - Benigni, A.

AU - Boccardo, P.

AU - Galbusera, M.

AU - Monteagudo, J.

AU - De Marco, L.

AU - Remuzzi, G.

AU - Ruggeri, Z. M.

PY - 1993

Y1 - 1993

N2 - Patients with chronic renal failure may experience a bleeding tendency and blood loss after surgical procedures or trauma. Altered platelet function has been indicated as the major cause of uremic bleeding, but its pathogenesis remains to be clarified. In two groups of patients with chronic renal disease of various etiology, the receptor function of glycoprotein (GP) Ib and GP IIb-IIIa complex was studied. Glycoprotein Ib was assessed with both 125I- von Willebrand factor (vWF) and 125I-asialo-vWF binding to platelets. Activation-dependent receptor function of the GP IIb-IIIa complex was studied with 125I-fibrinogen and 125I-vWF binding to washed platelets stimulated with adenosine diphosphate plus epinephrine (10 μmol/L each). Flow cytometric analyses on resting and stimulated platelets were performed using an activation-dependent, anti-GP IIb-IIIa monoclonal antibody (PAC1) as well as an activation-independent antibody (LJ-P1). Binding of PAC1 also was assessed in washed and stimulated platelets and in platelet-rich plasma before and after dialysis. We found that the activation-dependent receptor function of the GP IIb-IIIa complex is defective in uremia, as shown by decreased binding of both vWF and fibrinogen to stimulated platelets. Moreover, binding of the activation-dependent anti-GP IIb-IIIa monoclonal antibody, PAC1, was significantly decreased in uremia compared with that of the activation-independent antibody, LJ-P1. Thus, the number of GP IIb-IIIa receptors expressed on the platelet membrane is normal, but their activation is impaired. In contrast to the functional abnormality of GP IIb-IIIa, the vWF-binding activity of GP Ib was normal. Removal of components present in uremic plasma, either 'in vitro' by platelet washing or 'in vivo' by hemodialysis, markedly improved the GP IIb-IIIa defect. We conclude that a reversible abnormality of the activation-dependent binding activity of GP IIb-IIIa, due to dialyzable toxic substances, is likely to be a major component of the altered platelet function in uremia.

AB - Patients with chronic renal failure may experience a bleeding tendency and blood loss after surgical procedures or trauma. Altered platelet function has been indicated as the major cause of uremic bleeding, but its pathogenesis remains to be clarified. In two groups of patients with chronic renal disease of various etiology, the receptor function of glycoprotein (GP) Ib and GP IIb-IIIa complex was studied. Glycoprotein Ib was assessed with both 125I- von Willebrand factor (vWF) and 125I-asialo-vWF binding to platelets. Activation-dependent receptor function of the GP IIb-IIIa complex was studied with 125I-fibrinogen and 125I-vWF binding to washed platelets stimulated with adenosine diphosphate plus epinephrine (10 μmol/L each). Flow cytometric analyses on resting and stimulated platelets were performed using an activation-dependent, anti-GP IIb-IIIa monoclonal antibody (PAC1) as well as an activation-independent antibody (LJ-P1). Binding of PAC1 also was assessed in washed and stimulated platelets and in platelet-rich plasma before and after dialysis. We found that the activation-dependent receptor function of the GP IIb-IIIa complex is defective in uremia, as shown by decreased binding of both vWF and fibrinogen to stimulated platelets. Moreover, binding of the activation-dependent anti-GP IIb-IIIa monoclonal antibody, PAC1, was significantly decreased in uremia compared with that of the activation-independent antibody, LJ-P1. Thus, the number of GP IIb-IIIa receptors expressed on the platelet membrane is normal, but their activation is impaired. In contrast to the functional abnormality of GP IIb-IIIa, the vWF-binding activity of GP Ib was normal. Removal of components present in uremic plasma, either 'in vitro' by platelet washing or 'in vivo' by hemodialysis, markedly improved the GP IIb-IIIa defect. We conclude that a reversible abnormality of the activation-dependent binding activity of GP IIb-IIIa, due to dialyzable toxic substances, is likely to be a major component of the altered platelet function in uremia.

UR - http://www.scopus.com/inward/record.url?scp=0027376495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027376495&partnerID=8YFLogxK

M3 - Article

C2 - 8238012

AN - SCOPUS:0027376495

VL - 22

SP - 668

EP - 676

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -